Drug intelligence / Profile preview

LTC Cream

Development stage: Unknown
Lead developer: Andros Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

LTC Cream is a topical anesthetic formulation developed by Andros Pharmaceuticals, containing a combination of the amide-type local anesthetic lidocaine and the ester-type local anesthetic tetracaine. Categorized as a "super generic" by the developer, it is approved for use in topical anesthesia. The product functions by reversibly blocking voltage-gated sodium channels in the neuronal membrane. This action inhibits the ionic flux required for the initiation and conduction of nerve impulses, thereby providing localized anesthesia to the skin. LTC Cream is typically utilized to provide rapid and prolonged numbing for dermatological procedures, minor medical interventions, or cosmetic treatments.

Brand names: LTC Cream
Other names: lidocaine + tetracaine cream

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on LTC Cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTC Cream.

Explore the full profile